Cadence Pharmaceuticals Inc (CADX)
Quote as of 10:19 AM ET 07/29/2010 (NASDAQ GM)
| Last: 7.33 |
Change: $0.02 |
Percent Change: 0.27 |
Volume: 9,215 |
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates for use in the hospital setting. The Company has rights to one product candidate, Ofirmev, an intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The Company has in-licensed the exclusive United States and Canadian rights to Ofirmev from Bristol-Myers Squibb Company (BMS), which sells this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. Acetaminophen is available in over 600 combination and single-ingredient prescription and over-the-counter medicines, including tablet, caplet, orally-dosed liquid suspension, powder and suppository forms for both adults and children. The Company focuses on distributing Ofirmev primarily to drug wholesalers, who distributes the product to hospital pharmacies and other institutions.
Analyst Opinions
| |
Current |
1 Mo. |
3 Mo. |
| Strong Buy |
4.00 |
6.00 |
5.00 |
| Buy |
0.00 |
0.00 |
0.00 |
| Hold |
2.00 |
3.00 |
3.00 |
| Sell |
0.00 |
0.00 |
0.00 |
| Strong Sell |
1.00 |
1.00 |
1.00 |
|
|
Average Recommendation
| Current |
1.57 |
| 1 Mo. Ago |
1.50 |
| 3 Mo. Ago |
1.56 |
Recommendation Scale
| Strong Sell: 3.0 |
Hold: 2.0 |
Strong Buy: 1.0 |
|